Corticosteroid treatment in sarcoidosis

European Respiratory Journal

Volumn 28, Issue 3, 2006, Pages 627-636

  Grutters, J C ^a   van den Bosch, J M M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Corticosteroids; Sarcoidosis; Treatment

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; BUDESONIDE; CALCIUM; CELL ADHESION MOLECULE; CHEMOKINE; CHLOROQUINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; FLUTICASONE; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MECHANISM; DRUG UTILIZATION; EYE DISEASE; FOLLOW UP; HEART DISEASE; HUMAN; HYPERCALCEMIA; INHIBITION KINETICS; LUNG DISEASE; LUNG FUNCTION; LUNG GRANULOMA; LUNG PARENCHYMA; LUNG SARCOIDOSIS; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NEUROLOGIC DISEASE; OSTEOPOROSIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SARCOIDOSIS; SURVIVAL TIME; SYMPTOM; THORAX RADIOGRAPHY; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; DRUG THERAPY, COMBINATION; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; SARCOIDOSIS;

EID: 33751295995     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00105805     Document Type: Review

References (96)

1. American Thoracic Society, Statement on sarcoidosis. Am J Respir Crit Care Med 1999; 160: 736-755.
2. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993; 147: 1598-1600.
3. Popper HH. Epithelioid cell granulomatosis of the lung: new insights and concepts. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 32-46.
4. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981; 305: 429-434.
5. Yeager H Jr, Williams MC, Beekman JF, Bayly TC, Beaman BL. Sarcoidosis: analysis of cells obtained by bronchial lavage. Am Rev Respir Dis 1977; 116: 951-954.
6. Zissel G, Homolka J, Schlaak J, Schlaak M, Muller-Quernheim J. Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis. Am J Respir Crit Care Med 1996; 154: 713-719.
7. Agostini C, Semenzato G. Cytokines in sarcoidosis. Semin Respir Infect 1998; 13: 184-196.
8. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 24-31.
9. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 4952-4960.
10. Moller DR. Involvement of T cells and alterations in T cell receptors in sarcoidosis. Semin Respir Infect 1998; 13: 174-183.
11. Grunewald J, Janson CH, Eklund A, et al. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol 1992; 22: 129-135.
12. Newman LS. Aetiologies of sarcoidosis. Eur Respir Mon 2005; 32: 23-48.
13. Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005; 365: 1062-1072.
14. Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37: 357-364.
15. Selroos O, Klockars M, Kekomaki R, Pentinen K, Lindstrom P, Wager O. Circulating immune complexes in sarcoidosis. J Clin Lab Immunol 1980; 3: 129-132.
16. Grutters JC, Sato H, Welsh KI, du Bois RM. The importance of sarcoidosis genotype to lung phenotype. Am J Respir Cell Mol Biol 2003; 29: S59-S62.
17. Spagnolo P, Renzoni EA, Wells AU, et al. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome. Am J Respir Crit Care Med 2003; 168: 1162-1166.
18. Johns CJ, Michele TM. The clinical management of sarcoidosis. A 50-year experience at the Johns Hopkins Hospital. Medicine (Baltimore) 1999; 78: 65-111.
19. Möller DR. Treatment of sarcoidosis - from a basic science point of view. J Intern Med 2003; 253: 31-40.
20. Kruit A, Grutters JC, Ruven HJT, et al. TGF beta polymorphisms in sarcoidosis patients with and without pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 253.
21. Milburn HJ, Poulter LW, Dilmec A, Cochrane GM, Kemeny DM. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 1997; 108: 105-113.
22. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-190.
23. Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A. NF-κB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 50-56.
24. Rutherford RM, Kehren J, Staedtler F, et al. Functional genomics in sarcoidosis - reduced or increased apoptosis? Swiss Med Wkly 2001; 131: 459-470.
25. Conron M, Bondeson J, Pantelidis P, et al. Alveolar macrophages and T cells from sarcoid, but not normal lung, are permissive to adenovirus infection and allow analysis of NF-κB-dependent signaling pathways. Am J Respir Cell Mol Biol 2001; 25: 141-149.
26. Adcock IM, Ito K. Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis 2000; 55: 256-266.
27. Selroos O, Sellergren TL. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis 1979; 60: 215-221.
28. Pinkston P, Saltini C, Muller-Quernheim J, Crystal RG. Corticosteroid therapy suppresses spontaneous interleukin 2 release and spontaneous proliferation of lung T lymphocytes of patients with active pulmonary sarcoidosis. J Immunol 1987; 139: 755-760.
29. Turner-Warwick M, McAllister W, Lawrence R, Britten A, Haslam PL. Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? Thorax 1986; 41: 903-913.
30. James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967; 2: 526-528.
31. Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107: 609-614.
32. Roth I, Ehrke I, Eule H, Weinecke W. First report of a controlled therapeutic trial with prednisolone in pulmonary sarcoidosis. [Erster Bericht über eine kontrollierte klinische Untersuchung zur Prednisolon-Behandlung der thorakalen Sarkoidose]. Z Erkr Atmungsorgane 1975; 142: 49-58.
33. Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987; 87: 496-499.
34. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O, Finnish Pulmonary Sarcoidosis Study Group. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Chest 1999; 116: 424-431.
35. Pietinalho A, Tukiainen P, Haahtela T, Persson T, Selroos O. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121: 24-31.
36. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; CD001114.
37. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287: 1301-1307.
38. Gibson GJ, Prescott RJ, Muers MF, et al. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996; 51: 238-247.
39. Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121: 32-39.
40. Selroos O, Lofroos AB, Pietinalho A, Niemisto M, Riska H. Inhaled budesonide for maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1994; 11: 126-131.
41. Spiteri MA, Newman SP, Clarke SW, Poulter LW. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2: 218-224.
42. Erkkila S, Froseth B, Hellstrom PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5: 106-110.
43. Spiteri MA. Inhaled corticosteroids in pulmonary sarcoidosis. Postgrad Med J 1991; 67: 327-329.
44. Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236: 285-290.
45. du Bois RM, Greenhalgh PM, Southcott AM, Johnson NM, Harris TA. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13: 1345-1350.
46. McGrath D, Wells AU, Desai SR, et al. Efficacy, safety and tolerability of 3M HFA-134a beclomethasone dipropionate in pulmonary sarcoidosis. Am J Respir Crit Care Med 2002; 165: A495.
47. Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204.
48. Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8: 682-688.
49. Bechtel JJ, Starr T III, Dantzker DR, Bower JS. Airway hyperreactivity in patients with sarcoidosis. Am Rev Respir Dis 1981; 124: 759-761.
50. Marcias S, Ledda MA, Perra R, Severino C, Rosetti L. Aspecific bronchial hyperreactivity in pulmonary sarcoidosis. Sarcoidosis 1994; 11: 118-122.
51. Shorr AF, Torrington KG, Hnatiuk OW. Endobronchial involvement and airway hyperreactivity in patients with sarcoidosis. Chest 2001; 120: 881-886.
52. Kirsten D. Inhaled steroids for sarcoidosis? Eur Respir J 1995; 8: 679-681.
53. Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest 1996; 109: 535-539.
54. Hoitsma E, Marziniak M, Faber CG, et al. Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-2086.
55. Papadopoulos KI, Hornblad Y, Liljebladh H, Hallengren B. High frequency of endocrine autoimmunity in patients with sarcoidosis. Eur J Endocrinol 1996; 134: 331-336.
56. Hiraga H, Hiroe M, Iwai K. Guideline for the Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Diseases [in Japanese]. Tokyo, Japanese Ministry of Health and Welfare, 1993; pp. 23-24.
57. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88: 1006-1010.
58. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 133-137.
59. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005; 95: 143-146.
60. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83: 315-334.
61. Ishikawa T, Kondoh H, Nakagawa S, Koiwaya Y, Tanaka K. Steroid therapy in cardiac sarcoidosis. Increased left ventricular contractility concomitant with electrocardiographic improvement after prednisolone. Chest 1984; 85: 445-447.
62. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63: 86-108.
63. Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112: 220-228.
64. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 118-125.
65. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. QJM 1999; 92: 103-117.
66. Ohara K, Judson MA, Baughman RP, Clinical aspects of ocular sarcoidosis. Eur Respir Mon 2005; 10, 32: 188-209.
67. Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis HJ, Breebaart AC. Risk factors for ocular sarcoidosis. Doc Ophthalmol 1989; 72: 287-296.
68. Obenauf CD, Shaw HE, Sydnor CF, Klintworth GK. Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 1978; 86: 648-655.
69. Silver MR, Messner LV. Sarcoidosis and its ocular manifestations. J Am Optom Assoc 1994; 65: 321-327.
70. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155: 395-420.
71. Davies D, Curwen MP. Chloroquine in the treatment of sarcoidosis. A report from the Research Committee of the British Tuberculosis Association. Tubercle 1967; 48: 257-272.
72. Baltzan M, Mehta S, Kirkham TH, Cosio MG. Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197.
73. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1371-1376.
74. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-66.
75. Paramothayan S, Lasserson T, Walters EH. Immuno-suppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2003; CD003536.
76. Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-48.
77. Baughman RP, Lower EE, Therapy for sarcoidosis. Eur Respir Mon 2005; 32: 301-315.
78. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
79. Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 1999; 106: 111-118.
80. Hoitsma E, Sharma OP, Neurosarcoidosis. Eur Respir Mon 2005; 32: 164-187.
81. Baughman RP, Judson MA, Teirstein AS, Möller DR, Lower EE. Thalidomide for chronic sarcoidosis. Chest 2002; 122: 227-232.
82. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-74.
83. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy. Ann Intern Med 2001; 135: 27-31.
84. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005; 43: 7-11.
85. Baughman RP, Lower EE, Bradley DA, Raymond LA, Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005; 128: 1062-1047.
86. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-185.
87. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-1785.
88. Hunninghake GW, Costabel U, Ando M, et al. ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-173.
89. Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001; 18: Suppl. 32, 56s-68s.
90. James DG. Life-threatening situations in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 134-139.
91. DeRemee RA. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71: 388-393.
92. Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci 1986; 465: 702-712.
93. Sharma OP. Pulmonary sarcoidosis: management. J Postgrad Med 2002; 48: 135-141.
94. Conron M, Young C, Beynon HL. Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 2000; 39: 707-713.
95. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 1998; 53: 425-429.
96. Sharma OP. Renal sarcoidosis and hypercalcaemia. Eur Respir Mon 2005; 10, 32: 220-232.